

# Preoperative Predictors of Optimal Tumor Resectability in Patients With Epithelial Ovarian Cancer

Review began 07/25/2021

Review ended 01/18/2022

Published 01/19/2022

© Copyright 2022

Okunade et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Kehinde S. Okunade <sup>1,2</sup>, Adaiah P. Soibi-Harry <sup>1</sup>, Benedetto Osunwusi <sup>1</sup>, Ephraim Ohazurike <sup>1</sup>, Sarah O. John-olabode <sup>3</sup>, Adeyemi Okunowo <sup>4</sup>, Garba Rimi <sup>1</sup>, Omolola Salako <sup>5</sup>, Muisi Adenekan <sup>1</sup>, Rose Anorlu <sup>1</sup>

1. Obstetrics and Gynaecology, Lagos University Teaching Hospital, Lagos, NGA 2. Obstetrics and Gynaecology, College of Medicine, University of Lagos, Lagos, NGA 3. Haematology, College of Medicine, University of Lagos, Lagos, NGA 4. Obstetrics and Gynaecology, College of Medicine, University of Lagos/Lagos University Teaching Hospital, Lagos, NGA 5. Radiotherapy, Lagos University Teaching Hospital, Lagos, NGA

**Corresponding author:** Kehinde S. Okunade, [kehindeokunade@gmail.com](mailto:kehindeokunade@gmail.com)

---

## Abstract

### Background

Several studies have shown that whether complete tumor resection can be achieved during debulking surgery depends on various patient-related factors. However, none of these studies was conducted among patients with epithelial ovarian cancer (EOC) in sub-Saharan Africa. In this study, we aimed to determine the preoperative predictors of optimal tumor resectability (OTR) during primary debulking surgery (PDS) in patients with EOC.

### Methodology

In this study, we reviewed all patients with histologically diagnosed EOC who underwent PDS between January 2011 and December 2020. We included 83 patients with complete clinical records for subsequent data analysis. Descriptive statistics were computed for patients' data, and binary logistic regression analysis was used to assess the strength of associations between patients' preoperative characteristics and OTR.

### Results

The overall rate of OTR was 53.0%, while the rate in advanced EOC patients was 36.1%. In the univariate analyses, pleural effusion, ascites, tumor bilaterality, size of the largest tumor, retroperitoneal lymph nodes, omental caking, peritoneal thickening, significant extrapelvic tumor, serum cancer antigen-125 (CA-125) levels, and hemoglobin levels were recorded as the predictors of OTR. However, after adjusting for covariates in the final multivariate models, we found that the absence of moderate-to-large pleural effusion (odds ratio (OR) = 5.60; 95% confidence interval (CI) = 1.32, 23.71) and having serum CA-125 levels of  $\leq 370$  U/mL (OR = 6.80; 95% CI = 1.19, 38.79) were the overall independent predictors of OTR while not having any preexisting comorbidity (OR = 18.21; 95% CI = 2.40, 38.10), and the absence of pleural effusions (OR = 13.75; 95% CI = 1.80, 24.85) or enlarged retroperitoneal lymph nodes (OR = 11.95; 95% CI = 1.35, 16.07) were predictors of OTR in advanced EOC patients.

### Conclusions

We demonstrated that the radiological absence of pleural effusions and enlarged retroperitoneal lymph nodes and having no preexisting medical morbidity and serum CA-125 levels of  $\leq 370$  U/mL were the independent predictors of OTR during PDS. The preliminary data generated from this study can be used to develop variables for a prediction model in a future validation study.

---

**Categories:** Obstetrics/Gynecology, Radiology, Oncology

**Keywords:** primary debulking surgery, eoc, optimal tumor resectability, lagos, otr, ovarian cancer

## Introduction

In Nigeria, ovarian cancer (OC) is the second most common gynecologic cancer [1,2], with a peak incidence among women in their early 60s [2]. Approximately 90% of all histological types of OC are epithelial in origin [3], with over 70% of cases diagnosed at an advanced stage (International Federation of Gynecology and Obstetrics (FIGO), stage III-IV) [2]. Patients with epithelial ovarian cancer (EOC) are conventionally treated by primary debulking surgery (PDS) followed by adjuvant platinum-based chemotherapy [4]. One of the most important predictors of survival in patients with advanced EOC is the size of residual tumor after PDS [5]. Therefore, the goal of primary surgery is to achieve optimal tumor resectability (OTR). OTR is achieved when the residual tumor after surgery is less than 1 cm in the largest diameter [6]. Patients with advanced FIGO stage of EOC may undergo extensive debulking surgery and still have a significant residual tumor with a subsequent poor oncologic outcome and ultimate reduction in overall survival [2]. Therefore,

### How to cite this article

Okunade K S, Soibi-Harry A P, Osunwusi B, et al. (January 19, 2022) Preoperative Predictors of Optimal Tumor Resectability in Patients With Epithelial Ovarian Cancer. *Cureus* 14(1): e21409. DOI 10.7759/cureus.21409

patients with a low probability of optimal primary surgical debulking have the option of undergoing neoadjuvant chemotherapy (NACT) followed by interval debulking surgery to increase their chances of optimal surgical outcomes and subsequent improvement in survival [7,8].

Whether OTR can be achieved during debulking surgery depends on various patient factors such as age, comorbidity, extent, and location of the disease, as well as the skill and experience of the operating surgeon [9,10]. Therefore, it is important to develop an algorithm using these various preoperative factors derived from patient-specific characteristics and radiologic findings to predict patients with advanced EOC who may benefit from upfront or PDS. This study was aimed to determine the preoperative clinical and radiologic predictors of OTR during PDS in patients with EOC in Lagos, Nigeria.

## Materials And Methods

### Study design

We conducted a review of the health records of all OC cases that were managed at a university teaching hospital in Lagos, Nigeria between January 2011 and December 2020.

### Study setting

This study was conducted at a foremost public tertiary health institution in Lagos that offers specialized care including gynecologic oncology services. The hospital is the main referral center for other government-owned and private hospitals in Lagos and its neighboring states. Lagos State is the commercial capital of Nigeria with a population of 20 million [2].

### Eligibility criteria

We included 83 patients with histologically diagnosed EOC who underwent PDS during the review period. Women with non-epithelial OC, those who underwent NACT before debulking surgery, and those without complete clinical records or relevant data for analysis were excluded.

### Data collection

Data retrieved from patients' medical records included age, parity, menopausal status, body mass index (BMI), serum cancer antigen-125 (CA-125) levels, coexisting morbidity (such as hypertension, diabetes mellitus, kidney, and liver disease), presence of pleural effusion (on chest X-ray or chest computed tomography (CT) scan), ascites, tumor bilaterality, largest tumor diameter, the presence of retroperitoneal lymph nodes, omental caking (metastasis), peritoneal thickening and significant extrapelvic tumor with size greater than 2 cm on radiological imaging using abdominopelvic ultrasound and/or CT scan, and the outcome of PDS (optimal/suboptimal).

### Study endpoints

The study endpoints included (1) the rate of OTR, and (2) the preoperative predictors of OTR during PDS in patients with EOC. OTR is achieved when the residual tumor after PDS is less than 1 cm in the largest diameter [6].

### Statistical analysis


Data analysis was performed using SPSS version 27.0 (IBM Corp., Armonk, NY, USA), and descriptive statistics were computed for all patients' baseline characteristics. Patient characteristics were described using mean and standard deviation (if normally distributed) or median and interquartile range (if skewed) for continuous variables and by frequencies and percentages for categorical variables. Binary logistic regression models were used to estimate the odds ratios (ORs) and 95% confidence interval (CIs) for baseline demographic and clinical characteristics of patients. Adjustments were made to include factors with  $P < 0.10$  in the final multivariate models. Associations were considered statistically significant if  $P$ -values were  $< 0.05$ .

### Ethical considerations

We obtained ethical approval from the Health Research Ethics committee of the Lagos University Teaching Hospital (ADM/DCST/HREC/1912) before retrieving medical records and data collection. We conducted the study following the ethical principles of the Helsinki Declaration.

## Results

A total of 156 cases of OC were managed in the hospital during the period under review, of which 83 were eligible for inclusion in the final analysis. We excluded 18 women with non-EOC histotypes, 46 who had neoadjuvant chemotherapy and interval debulking surgery (NACT+IDS), five who failed to undergo treatment, and four with insufficient clinical data for analysis (Figure 1).



**FIGURE 1: Patient selection chart.**

EOC: epithelial ovarian cancer; NACT: neoadjuvant chemotherapy; IDS: interval debulking surgery

The mean age of the patients in the study group was  $54.5 \pm 11.5$  years. Patients were predominantly in the 50-59-year age group (n = 28, 33.7%), multiparous (n = 53, 63.8%), postmenopausal (n = 45, 54.2%), and had normal BMI (n = 37, 44.6%). More than two-thirds of the patients had coexisting medical morbidities (n = 64, 77.1%) and approximately half (n = 41, 49.4%) had significant ascites on radiological imaging (Table 1). Pleural effusions were seen in over two-thirds (n = 57, 68.7%) of the patients, while less than one-fifth had retroperitoneal lymphadenopathy (n = 16, 19.3%). Less than half of the patients (n = 35, 42.2%) had a bilateral tumor, with about one-third (n = 26, 31.3%) having omental metastasis. Peritoneal thickening (n = 33, 39.8%) and significant extrapelvic tumor greater than 2 cm (n = 36, 43.4%) were detected in approximately two-fifths of EOC patients. The median tumor size on radiological imaging and the median levels of other hematologic markers are presented in Table 1.

Characteristics	Number (%)
Mean age, years ( $\pm$ SD)	54.4 $\pm$ 11.5
20–29	1 (1.2)
30–39	11 (13.3)
40–49	17 (20.5)
50–59	28 (33.7)
60–69	14 (16.9)
$\geq$ 70	12 (14.5)
Median parity (IQR)	2 (1–3)
<2	30 (36.1)
2–5	48 (57.8)
>5	5 (6.0)
Menopausal status	
Pre-menopause	38 (45.8)
Postmenopause	45 (54.2)
Coexisting morbidity	
Yes	19 (22.9)
No	64 (77.1)

Mean BMI, kg/m <sup>2</sup> (±SD)	26.0 ± 4.8
Underweight <18.5	2 (2.4)
Normal weight 18.5–24.9	37 (44.6)
Overweight 25–29	26 (31.3)
Obese ≥30	18 (21.7)
Pleural effusions	
Yes	26 (31.3)
No	57 (68.7)
Ascites	
Yes	41 (49.4)
No	42 (50.6)
Tumor bilaterality	
Bilateral	35 (42.2)
Unilateral	48 (57.8)
Retroperitoneal lymph nodes	
Absent	67 (80.7)
Present	16 (19.3)
Omental cakeing	
Yes	26 (31.3)
No	57 (68.7)
Peritoneal thickening	
Yes	33 (39.8)
No	50 (60.2)
Extrapelvic tumor >2 cm	
Yes	36 (43.4)
No	47 (56.6)
Median largest tumor size, mm (IQR)	59 (43–88)
Median serum CA-125 levels, U/mL (IQR)	370 (144–675)
Median hemoglobin levels, g/dL (IQR)	10.5 (9.4–11.4)
Median white cells count, ×10 <sup>9</sup> /L (IQR)	6.5 (4.8–8.8)
Median platelet count, ×10 <sup>9</sup> /L (IQR)	333 (203–427)

**TABLE 1: Characteristics of patients with epithelial ovarian cancer (n = 83).**

BMI: body mass index; CA-125: cancer antigen-125; IQR: interquartile range; SD: standard deviation

The overall rate of OTR in this study was 53.0%, while the rate among EOC patients with advanced (FIGO stage III and IV) disease was 36.1%. As shown in the univariate analyses (Table 2), the absence of radiologically visible pleural effusion ( $P = 0.006$ ), ascites ( $P = 0.003$ ), retroperitoneal lymph nodes ( $P = 0.012$ ), omental caking ( $P = 0.003$ ), peritoneal thickening ( $P = 0.001$ ), and significant extrapelvic tumor ( $P = 0.001$ ) together with unilateral ovarian tumor ( $P = 0.001$ ), largest tumor diameter <60 mm ( $P = 0.037$ ), serum CA-125 levels of ≤370 U/mL ( $P = 0.001$ ), and hemoglobin levels of ≤10.5 g/dL ( $P = 0.096$ ) were the likely predictors of OTR during PDS. However, after adjustments in the final multivariate models (Table 3), having

no comorbidity and serum CA-125 levels of  $\leq 370$  U/mL (OR = 6.80; 95% CI = 1.19, 38.79; P = 0.031) and the absence of any radiological evidence of pleural effusions (OR = 5.60; 95% CI = 1.32, 23.71; P = 0.019) and enlarged retroperitoneal lymph nodes were the only independent predictors of optimal PDS.

Characteristics	Surgical resectability		Unadjusted OR (95% CI)	P-value
	Optimal n = 44 (%)	Suboptimal n = 39 (%)		
Coexisting morbidity				
No	33 (75.0)	31 (79.5)	0.77 (0.28–2.18)	0.627
Yes	11 (25.0)	8 (20.5)	1.00 (reference)	
BMI, kg/m <sup>2</sup>				
$\leq 25$	24 (54.5)	17 (43.6)	1.55 (0.65–3.70)	0.319
$> 25$	20 (45.5)	22 (56.4)	1.00 (reference)	
Pleural effusions				
No	37 (84.1)	18 (46.2)	6.17 (2.21–17.17)	0.001
Yes	7 (15.9)	21 (53.8)	1.00 (reference)	
Ascites				
No	29 (65.9)	13 (33.3)	3.87 (1.55–9.63)	0.003
Yes	15 (34.1)	26 (66.7)	1.00 (reference)	
Tumor bilaterality				
Unilateral	34 (77.3)	14 (35.9)	6.07 (2.32–15.89)	0.001
Bilateral	10 (22.7)	25 (64.1)	1.00 (reference)	
Largest tumor size, mm				
$< 60$	27 (61.4)	15 (38.5)	4.44 (1.30–15.24)	0.037
$\geq 60$	17 (38.6)	24 (61.5)	1.00 (reference)	
Lymph nodes				
No	40 (90.9)	27 (69.2)	1.55 (0.65–3.70)	0.012
Yes	4 (9.1)	12 (30.8)	1.00 (reference)	
Omental caking				
No	37 (84.1)	21 (53.8)	4.53 (1.63–12.62)	0.003
Yes	7 (15.9)	18 (46.2)	1.00 (reference)	
Peritoneal thickening				
No	37 (79.5)	13 (35.9)	10.57 (3.71–30.11)	0.001
Yes	7 (20.5)	26 (64.1)	1.00 (reference)	
Extrapelvic tumor $> 2$ cm				
No	33 (75.0)	15 (38.5)	4.80 (1.88–12.28)	0.001
Yes	11 (25.0)	24 (61.5)	1.00 (reference)	
Serum CA-125 levels, U/mL				
$\leq 370$	33 (75.0)	9 (23.1)	10.00 (3.64–27.46)	0.001
$> 370$	11 (25.0)	30 (76.9)	1.00 (reference)	
Hemoglobin levels, g/dL				
$\leq 10.5$	19 (43.2)	24 (61.5)	0.48 (0.20 – 1.14)	0.096

>10.5	25 (56.8)	15 (38.5)	1.00 (reference)	
White cells count, $\times 10^9/L$				
$\leq 6.5$	21 (47.7)	22 (56.4)	0.71 (0.30–1.68)	0.429
>6.5	23 (52.3)	17 (43.6)	1.00 (reference)	
Platelet count, $\times 10^9/L$				
$\leq 333$	22 (50.0)	20 (51.3)	3.87 (1.55–9.63)	0.907
>333	22 (50.0)	19 (48.7)	1.00 (reference)	

**TABLE 2: Univariate analyses of preoperative predictors of surgical outcomes in epithelial ovarian cancer (n = 83).**

BMI: body mass index; CA-125: cancer antigen-125; CI: confidence interval; OR: odds ratio

Characteristics	Category	Multivariate	
		Adjusted OR (95% CI)	P-value
Ascites	No vs. yes	1.83 (0.38–8.79)	0.452
Pleural effusions	No vs. yes	5.60 (1.32–23.71)	0.019
Tumor bilaterality	Unilateral vs. bilateral	2.02 (0.43–9.52)	0.374
Largest tumor size	<60 vs. $\geq 60$ mm	2.86 (0.74–11.06)	0.127
Omental caking	No vs. yes	0.59 (0.12–2.84)	0.506
Peritoneal thickening	No vs. yes	2.76 (0.51–14.92)	0.237
Extrapelvic tumor >2 cm	No vs. yes	2.45 (0.51–11.68)	0.262
Retroperitoneal lymph nodes	Absent vs. present	3.42 (0.42–28.16)	0.253
Serum CA-25 levels	$\leq 370$ vs. $>370$ U/mL	6.80 (1.19–38.79)	0.031
Hemoglobin concentration	$\leq 10.5$ vs. $>10.5$ g/dL	0.99 (0.27–3.63)	0.984

**TABLE 3: Multivariate analyses of preoperative predictors of optimal surgical resection in epithelial ovarian cancer (n = 83).**

CA-125: cancer antigen-125; CI: confidence interval; OR: odds ratio

Furthermore, as shown in the univariate analyses reported in Table 4, the absence of preexisting comorbidity ( $P = 0.088$ ) and serum CA-125 levels ( $P = 0.005$ ) together with the absence of radiological evidence of pleural effusion ( $P = 0.007$ ), tumor bilaterality ( $P = 0.037$ ), significant preoperative tumor size ( $P = 0.059$ ), peritoneal thickening ( $P = 0.001$ ), and retroperitoneal lymph nodes ( $P = 0.001$ ) were the likely predictors of OTR in patients with advanced EOC. On multivariate analyses, the absence of medical comorbidities (OR = 18.21; 95% CI = 2.40, 38.10;  $P = 0.005$ ) and radiological absence of pleural effusions (OR = 13.75; 95% CI = 1.80, 24.85;  $P = 0.011$ ) and retroperitoneal lymph nodes (OR = 11.95; 95% CI = 1.35, 16.07;  $P = 0.026$ ) were independently associated with OTR in patients with FIGO stage III and IV disease during PDS.

Characteristics	Category	Optimal tumor resection		
		Univariate	Multivariate	
		P-value	Adjusted OR (95% CI)	P-value
Comorbidity	No vs. yes	0.045	18.21 (2.40–38.10)	0.005
BMI, kg/m <sup>2</sup>	≤25 vs. >25	0.923	-	-
Ascites	No vs. yes	0.554	-	-
Pleural effusions	No vs. yes	0.007	13.75 (1.80–24.85)	0.011
Tumor bilaterality	Unilateral vs. bilateral	0.037	2.37 (0.44–12.87)	0.319
Largest tumor size, mm	<60 vs. ≥60	0.090	4.75 (0.84–26.91)	0.078
Omental caking	No vs. yes	0.147	-	-
Peritoneal thickening	No vs. yes	0.001	6.21 (0.74–52.13)	0.093
Extrapelvic tumor >2 cm	No vs. yes	0.225	-	-
Retroperitoneal lymph nodes	Absent vs. present	0.001	11.95 (1.35–16.07)	0.026
Serum CA-25 levels	≤370 vs. >370 U/mL	0.005	4.32 (0.55–34.04)	0.165
Hemoglobin concentration, g/dL	≤10.5 vs. >10.5	0.225	-	-
White cell count, ×10 <sup>9</sup> /L	≤6.5 vs. >6.5	0.411	-	-
Platelet count, ×10 <sup>9</sup> /L	≤333 vs. >333	0.662	-	-

**TABLE 4: Univariate and multivariate analyses of preoperative predictors of optimal surgical resection in advanced epithelial ovarian cancer (n = 61).**

BMI: body mass index; CA-125: cancer antigen-125; OR: odds ratio

## Discussion

This study investigated the preoperative predictors of optimal PDS in patients with EOC in Lagos, Nigeria. This was based on the report of a paradigm shift by Horowitz et al. [11] who reported that if an optimal surgical outcome is difficult to attain with upfront surgical debulking, then the use of NACT followed by IDS may be superior to PDS, especially in patients with advanced-stage disease. In this study, we found that the radiological absence of pleural effusion and serum CA-125 levels of ≤370 U/mL were the only independent predictors of OTR in patients with EOC. Furthermore, in patients with advanced-stage III and IV disease, the absence of preexisting comorbidity, pleural effusions (on chest imaging), and retroperitoneal lymph nodes were the independent predictors of OTR.

The overall rate of OTR in this study (53.0%) is higher than the rates reported in previous studies by Kim et al. (40.0%) [12], Rutten et al. (46.4%), [8], and Gerestein et al. (45.0%) [13]. However, the rate of OTR recorded in patients with advanced EOC only (36.1%) in our study is similar to the rates reported in previous studies that included only patients with advanced (FIGO stage III and IV) disease. Only a few studies have reported on the predictors of optimal surgical debulking in patients with EOC, most of which relied on radiologic predictors [14–17], unlike our study that used patients' clinical parameters such as the presence of medical comorbidities, BMI, hematologic, and biochemical markers, in addition to the radiologic evidence of pleural effusion, ascites, tumor bilaterality, largest tumor size, retroperitoneal lymphadenopathy, omental cake, significant extrapelvic tumor, and peritoneal thickening. Our results showed that the presence of pleural effusions on preoperative imaging increased the risk of suboptimal debulking by up to 14 times in patients with advanced EOC. In patients with OC, moderate-to-large pleural effusions have been reported to be more likely to be malignant [18], a finding that automatically upstages the disease to at least FIGO stage IV [19], thus suggesting the increased tendency of having a residual disease after PDS [20].

The most commonly studied biomarker for EOC is serum CA-125 level [21]. Chi et al. [22] in 2000 and Kang et al. [9] in 2010 reported that preoperative serum CA-125 levels greater than 500 U/mL were strongly associated with suboptimal surgical debulking in patients with advanced EOC. This was further corroborated by the findings of our study where a lower serum CA-125 cut-off level of 370 U/mL was associated with

increased odds of OTR. The most appropriate cut-off of CA-125 remains somewhat controversial, and a future validation study can help confirm the most appropriate value. We reported a significant reduction in the rate of OTR among advanced EOC patients with coexisting medical morbidities, which may be explained by the reduced tendency of these patients to tolerate prolonged anesthesia and extensive tumor debulking with a resultant decrease in available surgical time for optimal resection of all visible tumors.

Metastasis via retroperitoneal lymph nodes is one of the main pathways of OC spread at a rate that is as high as 44-53% in advanced OC [23,24]. Only 19.30% of patients in our study had any radiologic evidence of enlarged retroperitoneal lymph nodes, but the rate of microscopic lymph node metastasis, even though not reported, could be much higher. Retroperitoneal lymph node enlargement on radiologic imaging was reported to be a predictor of OTR in our study. This corroborated the findings of Bristow et al. [25] and Suidan et al. [26] who reported suprarenal para-aortic lymph node enlargement ( $\geq 1$  cm) as one of the most important predictive factors for suboptimal debulking in patients with advanced OC.

In this study, the rate of successful OTR was 65.9% in patients with no visible ascites on imaging and 34.1% in patients with EOC and ascites. This is, however, in contrast to the study by Randle et al. [27] who reported that the rate of complete cytoreductive surgery in patients with OC and malignant ascites remained 100%. Massive ascites may affect the respiratory and circulatory functions of patients with subsequent decreased ability to withstand prolonged anesthesia and extensive surgical resection [28]. Our study is also corroborated by the findings from other previous studies [29,30] that reported ascites as one of the predictors of suboptimal surgical debulking in OC patients. However, no independent association was recorded between ascites and OTR in the final multivariate models used in our study.

A significant strength of this study is the initial review of all cases and the performance of debulking surgeries in a multidisciplinary team setting involving the gynecologic oncologist, general/colorectal surgeon, and urologist, with the reduction in the influence of this factor on the oncologic outcome (OTR) being examined in the study. However, the study has a few limitations. First, because this was a single-center retrospective study, the findings cannot be generalizable to other gynecologic oncology units or centers in the country. Second, the number of patients who were eligible for PDS during the review period was relatively small, limiting the in-depth analysis, conclusions, and generalizability of the study findings. The important influence of the cadre and experience of the lead surgeons on the OTR rate was not assessed as the available data in the review was not sufficient to examine this. We intend to investigate this in future research work. In addition, this study only included patients who had PDS followed by adjuvant chemotherapy with the exclusion of patients treated with NACT who could have had a high proportion of the authors' identification predictors that could have a significant impact on the study endpoints. Finally, the lack of data on patients' performance status, which is evidence of patients' cardiovascular and respiratory stability, could significantly influence the extent of the upfront debulking surgery and act as an important confounding factor.

## Conclusions

It is important to predict patients with advanced EOC who may benefit from upfront primary surgical debulking with the use of certain preoperative clinical and radiological parameters to reduce the surgical morbidity and improve the oncologic outcome of these patients. In this study, we demonstrated that having no preexisting comorbidity, serum CA-125 of  $\leq 370$  U/mL, and absence of radiologic evidence of large pleural effusions and enlarged retroperitoneal lymph nodes were independent predictors of OTR. However, this is a pilot study among women with EOC in Nigeria. The preliminary data generated will be further tested in a future validation study.

## Additional Information

### Disclosures

**Human subjects:** Consent was obtained or waived by all participants in this study. Health Research Ethics Committee of the Lagos University Teaching Hospital issued approval ADM/DCST/HREC/1912. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

### Acknowledgements

The authors appreciate the staff of the Medical Records Department of the hospital for assisting with the retrieval of the patients' medical records. We also appreciate the resident doctors of the Oncology and Pathological Studies (OPS) Unit of the Department of Obstetrics and Gynaecology for their role in data retrieval and collation. The work reported in this study was supported in part by the Conquer Cancer International Innovation Grant under Project ID 16576 and the Fogarty International Center of the National



Institutes of Health under Award Numbers D43TW010934, D43TW010134, and D43TW010543. The views expressed in this publication are those of the authors and do not necessarily reflect the official views of the American Society of Clinical Oncology® or Conquer Cancer® and the National Institutes of Health.

## References

1. Onyiaorah IV, Anunobi CC, Banjo AA, Fatima AA, Nwankwo KC: Histopathological patterns of ovarian tumours seen in Lagos University Teaching Hospital: a ten year retrospective study. *Nig Q J Hosp Med.* 2011, 21:114-8.
2. Okunade KS, Okunola H, Okunowo AA, Anorlu RI: A five year review of ovarian cancer at a tertiary institution in Lagos, South-West, Nigeria. *Niger J Gen Pract.* 2016, 14:23-7. [10.4103/1118-4647.187901](https://doi.org/10.4103/1118-4647.187901)
3. Kosary CL: Cancer of the ovary. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. SEER Program. Ries LA, Young JL, Keel GE, Eisner MP, Lin YD, Horner MJ (ed): National Cancer Institute, Bethesda, MD; 2007. 133-44.
4. Karlsen MA, Fagö-Olsen C, Høgdall E, et al.: A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study. *Tumour Biol.* 2016, 37:12619-26. [10.1007/s13277-016-5166-z](https://doi.org/10.1007/s13277-016-5166-z)
5. Okunade KS, Adetuyi IE, Adenekan M, Ohazurike E, Anorlu RI: Risk predictors of early recurrence in women with epithelial ovarian cancer in Lagos, Nigeria. *Pan Afr Med J.* 2020, 36:272. [10.11604/pamj.2020.36.272.17827](https://doi.org/10.11604/pamj.2020.36.272.17827)
6. Chang SJ, Hodeib M, Chang J, Bristow RE: Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. *Gynecol Oncol.* 2013, 130:493-8. [10.1016/j.ygyno.2013.05.040](https://doi.org/10.1016/j.ygyno.2013.05.040)
7. Vergote I, Tropé CG, Amant F, et al.: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. *N Engl J Med.* 2010, 363:943-53. [10.1056/NEJMoa0908806](https://doi.org/10.1056/NEJMoa0908806)
8. Rutten IJ, van de Laar R, Kruitwagen RF, et al.: Prediction of incomplete primary debulking surgery in patients with advanced ovarian cancer: an external validation study of three models using computed tomography. *Gynecol Oncol.* 2016, 140:22-8. [10.1016/j.ygyno.2015.11.022](https://doi.org/10.1016/j.ygyno.2015.11.022)
9. Kang S, Kim TJ, Nam BH, Seo SS, Kim BG, Bae DS, Park SY: Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. *J Surg Oncol.* 2010, 101:13-7. [10.1002/jso.21398](https://doi.org/10.1002/jso.21398)
10. Aletti GD, Gostout BS, Podratz KC, Cliby WA: Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. *Gynecol Oncol.* 2006, 100:33-7. [10.1016/j.ygyno.2005.07.123](https://doi.org/10.1016/j.ygyno.2005.07.123)
11. Horowitz NS, Miller A, Rungruang B, et al.: Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. *J Clin Oncol.* 2015, 33:937-43. [10.1200/JCO.2014.56.3106](https://doi.org/10.1200/JCO.2014.56.3106)
12. Kim HJ, Choi CH, Lee YY, Kim TJ, Lee JW, Bae DS, Kim BG: Surgical outcome prediction in patients with advanced ovarian cancer using computed tomography scans and intraoperative findings. *Taiwan J Obstet Gynecol.* 2014, 53:543-7. [10.1016/j.tjog.2013.10.041](https://doi.org/10.1016/j.tjog.2013.10.041)
13. Gerestein CG, Eijkemans MJ, Bakker J, Elgersma OE, van der Burg ME, Kooi GS, Burger CW: Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer. *Anticancer Res.* 2011, 31:4043-9.
14. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. *J Clin Oncol.* 2002, 20:1248-59. [10.1200/JCO.2002.20.5.1248](https://doi.org/10.1200/JCO.2002.20.5.1248)
15. Nelson BE, Rosenfield AT, Schwartz PE: Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. *J Clin Oncol.* 1993, 11:166-72. [10.1200/JCO.1993.11.1.166](https://doi.org/10.1200/JCO.1993.11.1.166)
16. Meyer JI, Kennedy AW, Friedman R, Ayoub A, Zepp RC: Ovarian carcinoma: value of CT in predicting success of debulking surgery. *AJR Am J Roentgenol.* 1995, 165:875-8. [10.2214/ajr.165.4.7676985](https://doi.org/10.2214/ajr.165.4.7676985)
17. Qayyum A, Coakley FV, Westphalen AC, Hricak H, Okuno WT, Powell B: Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. *Gynecol Oncol.* 2005, 96:301-6. [10.1016/j.ygyno.2004.06.054](https://doi.org/10.1016/j.ygyno.2004.06.054)
18. Kim KW, Choi HJ, Kang S, et al.: The utility of multi-detector computed tomography in the diagnosis of malignant pleural effusion in the patients with ovarian cancer. *Eur J Radiol.* 2010, 75:230-5. [10.1016/j.ejrad.2009.04.061](https://doi.org/10.1016/j.ejrad.2009.04.061)
19. Prat J: Staging classification for cancer of the ovary, fallopian tube, and peritoneum. *Int J Gynaecol Obstet.* 2014, 124:1-5. [10.1016/j.ijgo.2013.10.001](https://doi.org/10.1016/j.ijgo.2013.10.001)
20. Okunade KS, Adejimi AA, Ohazurike EO, et al.: Predictors of survival outcomes after primary treatment of epithelial ovarian cancer in Lagos, Nigeria. *JCO Glob Oncol.* 2021, 7:89-98. [10.1200/GO.20.00450](https://doi.org/10.1200/GO.20.00450)
21. Gómez-Hidalgo NR, Martínez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL, Ramirez PT: Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: time to incorporate laparoscopic assessment into the standard of care. *Gynecol Oncol.* 2015, 137:553-8. [10.1016/j.ygyno.2015.05.049](https://doi.org/10.1016/j.ygyno.2015.05.049)
22. Chi DS, Venkatraman ES, Masson V, Hoskins WJ: The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. *Gynecol Oncol.* 2000, 77:227-31. [10.1006/gyno.2000.5749](https://doi.org/10.1006/gyno.2000.5749)
23. Harter P, Gnauert K, Hils R, Lehmann TG, Fisseler-Eckhoff A, Traut A, du Bois A: Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. *Int J Gynecol Cancer.* 2007, 17:1238-44. [10.1111/j.1525-1438.2007.00931.x](https://doi.org/10.1111/j.1525-1438.2007.00931.x)
24. Morice P, Joulie F, Camatte S, et al.: Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. *J Am Coll Surg.* 2003, 197:198-205. [10.1016/S1072-7515\(03\)00234-5](https://doi.org/10.1016/S1072-7515(03)00234-5)
25. Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble EL, Montz FJ: A model for predicting

- surgical outcome in patients with advanced ovarian carcinoma using computed tomography. *Cancer*. 2000, 89:1532-40. [10.1002/1097-0142\(20001001\)89:7<1532::aid-cnrcr17>3.0.co;2-a](https://doi.org/10.1002/1097-0142(20001001)89:7<1532::aid-cnrcr17>3.0.co;2-a)
26. Suidan RS, Ramirez PT, Sarasohn DM, et al.: A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. *Gynecol Oncol*. 2014, 134:455-61. [10.1016/j.ygyno.2014.07.002](https://doi.org/10.1016/j.ygyno.2014.07.002)
  27. Randle RW, Swett KR, Swords DS, Shen P, Stewart JH, Levine EA, Votanopoulos KI: Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. *Ann Surg Oncol*. 2014, 21:1474-9. [10.1245/s10434-013-3224-y](https://doi.org/10.1245/s10434-013-3224-y)
  28. Ba M, Long H, Zhang X, et al.: Different sequential approaches of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treating ovarian cancer with malignant ascites. *J Cancer Res Clin Oncol*. 2014, 140:1497-506. [10.1007/s00432-014-1692-5](https://doi.org/10.1007/s00432-014-1692-5)
  29. Arab M, Jamdar F, Sadat Hosseini M, Ghodssi- Ghasemabadi R, Farzaneh F, Ashrafganjoei T: Model for prediction of optimal debulking of epithelial ovarian cancer. *Asian Pac J Cancer Prev*. 2018, 19:1319-24. [10.22034/APJCP.2018.19.5.1319](https://doi.org/10.22034/APJCP.2018.19.5.1319)
  30. Janco JM, Glaser G, Kim B, et al.: Development of a prediction model for residual disease in newly diagnosed advanced ovarian cancer. *Gynecol Oncol*. 2015, 138:70-7. [10.1016/j.ygyno.2015.04.013](https://doi.org/10.1016/j.ygyno.2015.04.013)